{"id":"NCT00120523","sponsor":"MEDA Pharma GmbH & Co. KG","briefTitle":"5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis","officialTitle":"Five-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 to Less Than 12 Months of Age With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-04","primaryCompletion":"2010-10","completion":"2010-10","firstPosted":"2005-07-18","resultsPosted":"2013-01-16","lastUpdate":"2022-02-11"},"enrollment":2418,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Pimecrolimus","otherNames":["Elidel"]},{"type":"DRUG","name":"Topical corticosteroids","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"The primary purpose of this study is to investigate the safety of pimecrolimus cream 1% in the long-term treatment (up to 5 years) of atopic dermatitis (eczema) in patients less than 12 months of age compared to topical corticosteroids (TCS).","primaryOutcome":{"measure":"Safety Assessed by Adverse Events","timeFrame":"throughout the 5-year study","effectByArm":[{"arm":"Pimecrolimus","deltaMin":8.6,"sd":null},{"arm":"Topical Corticosteroids","deltaMin":7.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":31,"countries":["United States","Germany"]},"refs":{"pmids":["25802354"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":247,"n":1205},"commonTop":["Nasopharyngitis","Pyrexia","Bronchitis","Otitis media","Diarrhoea"]}}